The Latest Cardiac and Vascular News
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 […]
MicroVention Now Offers a Fully Integrated, Comprehensive Stroke Portfolio, Delivering Breakthrough Innovation from Access to Revascularization ALISO VIEJO, Calif.–(BUSINESS WIRE)–MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment. ERIC received […]
ATCOR and Datacubed Health partner on a novel remote trial solution to integratedigital vascular biomarker patient monitoring within the Datacubed Health PatientEngagement Platform IRVINE, Calif., June 26, 2023 /PRNewswire/ — ATCOR Medical, subsidiary of CardieX and developer of innovative medical devices and digital solutions to personalize healthcare and improve clinical trial patient outcomes, today announces it […]
First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention, Especially for Those Living with Diabetes SAN DIEGO, June 24, 2023 /PRNewswire/ — Today, a new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with […]
Collaboration Bolsters LianMedical’s Mission to Bring Novel Technologies to the Asian Market and Supports Global Expansion of CereVasc’s Technology BOSTON and SHANGHAI, June 26, 2023 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, and LianMedical, a medical device company focused on accelerating the introduction of breakthrough medical […]
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company […]
Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases […]
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates study results and Premarket Approval (PMA) submission in H2 2024, potential U.S. approval in H1 2025 TEL AVIV, Israel, June […]
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it is set to join the broad-market Russell 3000® Index, the small-cap Russell 2000® Index, and the […]
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the […]
